Medidata Solutions (NASDAQ:MDSO) was upgraded by equities researchers at Dougherty & Co from a “neutral” rating to a “buy” rating in a research report issued on Monday, November 13th, Marketbeat.com reports. The brokerage currently has a $75.00 target price on the stock. Dougherty & Co’s price objective indicates a potential upside of 11.36% from the company’s previous close.
Several other research analysts have also recently weighed in on MDSO. J P Morgan Chase & Co boosted their price objective on shares of Medidata Solutions to $87.00 and gave the company an “overweight” rating in a report on Tuesday, July 18th. Morgan Stanley upped their target price on shares of Medidata Solutions from $74.00 to $86.00 and gave the company an “overweight” rating in a report on Thursday, July 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 target price (up from $75.00) on shares of Medidata Solutions in a report on Friday, July 21st. Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Friday, July 21st. Finally, Citigroup reiterated a “buy” rating and set a $95.00 price objective (up previously from $94.00) on shares of Medidata Solutions in a research report on Monday, July 24th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Medidata Solutions presently has a consensus rating of “Buy” and a consensus target price of $83.54.
Medidata Solutions (NASDAQ MDSO) opened at $67.35 on Monday. The company has a quick ratio of 3.37, a current ratio of 1.29 and a debt-to-equity ratio of 0.61. Medidata Solutions has a 52 week low of $47.77 and a 52 week high of $85.92. The stock has a market cap of $3,940.00, a P/E ratio of 80.29, a PEG ratio of 4.15 and a beta of 1.77.
In related news, EVP Michael Pray sold 5,944 shares of the firm’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $70.47, for a total value of $418,873.68. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Michael L. Capone sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $66.33, for a total transaction of $331,650.00. The disclosure for this sale can be found here. Insiders sold a total of 225,944 shares of company stock worth $15,568,274 in the last ninety days. 5.80% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. California Public Employees Retirement System increased its position in Medidata Solutions by 1.2% during the 3rd quarter. California Public Employees Retirement System now owns 104,076 shares of the company’s stock valued at $8,124,000 after purchasing an additional 1,276 shares during the period. Zions Bancorporation purchased a new position in Medidata Solutions during the 3rd quarter valued at about $256,000. Jane Street Group LLC increased its position in Medidata Solutions by 112.8% during the 3rd quarter. Jane Street Group LLC now owns 9,505 shares of the company’s stock valued at $742,000 after purchasing an additional 5,038 shares during the period. AMP Capital Investors Ltd purchased a new position in Medidata Solutions during the 3rd quarter valued at about $2,194,000. Finally, Polen Capital Management LLC purchased a new position in Medidata Solutions during the 3rd quarter valued at about $205,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with our FREE daily email newsletter.